CagriSema 2.4 mg 2.4 mg 可改善超重或肥胖但无 2 型糖尿病的成年人的代谢综合征：REDEFINE 1 的一项事后分析.pdf

1、CagriSema 2.4 mg/2.4 mg improves metabolic syndrome in adults with overweight or obesity,without type 2 diabetes:A post hoc analysis of REDEFINE 1Matthias Blher1*,Kasper Adelborg2,Melanie J.Davies3,Ildiko Lingvay4,Christian Bge Lyndgaard2,Rasmus Srrig2,John P.H.Wilding5,Ania M.Jastreboff6PO4.008http

2、s:/ QR code or visit the website below for:Poster+SlidesAim To evaluate the effect of CagriSema 2.4 mg/2.4 mg on metabolic syndrome in adults with overweight or obesity,without type 2 diabetes(T2D),in a post hoc analysis of the REDEFINE 1 trial.Introduction In the REDEFINE 1 trial(NCT05567796)of adu

3、lts with overweight or obesity,without T2D,treatment with a fixed-dose combination of the glucagon-like peptide-1 receptor agonist,semaglutide,and long-acting amylin analogue,cagrilintide(CagriSema 2.4 mg/2.4 mg)reduced mean body weight by 22.7%using the trial product estimand.1 CagriSema 2.4 mg/2.4

4、 mg also resulted in improvements in systolic blood pressure(SBP),waist circumference,glycated haemoglobin and lipid levels.1 Metabolic syndrome is a cluster of risk for cardiovascular disease,defined as the presence of three or more of elevated blood pressure,dyslipidaemia(raised triglycerides and

5、lowered high-density lipoprotein HDL cholesterol),elevated fasting plasma glucose(FPG)and elevated waist cirumference.2 The estimated global prevalence of metabolic syndrome is increasing and,in 2023,was 31%among females and 26%among males.3Methods REDEFINE 1 was a phase 3a,double-blind,placebo-and

6、active-controlled 68-week trial(Figure 1).Participants with a body mass index(BMI)30 kg/m2,or 27 kg/m2 with 1 obesity-related complication,were randomised 7:3:3:21 to once-weekly placebo,cagrilintide 2.4 mg,semaglutide 2.4 mg or CagriSema 2.4 mg/2.4 mg,plus lifestyle intervention.Outcomes for this p